Sign in →

Test ID: HLA57 HLA-B 5701 Genotype, Abacavir Hypersensitivity, Blood

Reporting Name

HLA-B 5701 Genotype, Abacavir, B

Useful For

Identifying individuals with an increased risk of hypersensitivity reactions to abacavir, based on the presence of the human leukocyte antigen HLA-B*57:01 allele

Testing Algorithm

See Abacavir Hypersensitivity Testing and Initial Patient Management Algorithm in Special Instructions

Specimen Type

Whole Blood EDTA

Specimen Required

Multiple whole blood EDTA genotype tests can be performed on a single specimen. See Multiple Whole Blood EDTA Genotype Tests in Special Instructions for a list of tests that can be ordered together.


Container/Tube: Lavender top (EDTA)

Specimen Volume: 3 mL

Collection Instructions: Send specimen in original tube.

Specimen Minimum Volume

0.3 mL

Specimen Stability Information

Specimen Type Temperature Time
Whole Blood EDTA Ambient (preferred)

Reference Values


An interpretive report will be provided.

Day(s) and Time(s) Performed

Monday, Wednesday through Friday; 10 a.m.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
HLA57 HLA-B 5701 Genotype, Abacavir, B In Process


Result ID Test Result Name Result LOINC Value
89346 HLA-B 5701 Result 42358-2
29315 HLA-B 5701 Interpretation 69047-9
29316 HLA-B 5701 Reviewed by 18771-6

Clinical Information

The human leukocyte antigen (HLA) genes help the immune system recognize and respond to foreign substances (such as viruses and bacteria). The HLA-B gene encodes a class 1 HLA molecule in the major histocompatibility complex (MHC), which acts by presenting peptides to immune cells. There are more than 1,500 different HLA-B alleles identified, one of which is the HLA-B*57:01 allele. Frequency of the HLA-B*57:01 allele varies with ethnicity, with a frequency of 6% to 7% in European populations, and up to 20% in Southwest Asian populations.


The HLA-B*57:01 allele has been associated with hypersensitivity to abacavir, a highly effective nucleoside analog reverse-transcriptase inhibitor used to treat HIV infection and AIDS. Per the Clinical Pharmacogenomics Implementation Consortium (CPIC) dosing guidelines for abacavir and HLA-B, individuals who are positive for the HLA-B*57:01 allele are at an increased risk for abacavir hypersensitivity and it is not recommended for use in treating these individuals.


Hypersensitivity reactions, which generally occur during the first 6 weeks of treatment, are often nonspecific and include skin rashes, gastrointestinal symptoms (eg, nausea, vomiting, diarrhea, and abdominal pain), and respiratory symptoms. Fatalities have been reported with abacavir hypersensitivity. Prospective testing for the HLA-B*57:01 genotype and excluding HLA-B*57:01-positive individuals from treatment with abacavir decreases the incidence of abacavir hypersensitivity.


See Abacavir Hypersensitivity Testing and Initial Patient Management Algorithm in Special Instructions.


Positivity for human leukocyte antigen allele HLA-B*57:01 confers high risk for hypersensitivity to abacavir.


See Abacavir Hypersensitivity Testing and Initial Patient Management Algorithm in Special Instructions.


For additional information regarding pharmacogenomic genes and their associated drugs, see the Pharmacogenomic Associations Tables in Special Instructions. This resource also includes information regarding enzyme inhibitors and inducers, as well as potential alternate drug choices.

Clinical Reference

1. Saag M, Balu R, Brachman P, et al: High sensitivity of HLA-B*5701 in whites and blacks in immunologically-confirmed cases of abacavir hypersensitivity. Fourth IAS Conference on HIV Pathogenesis, Treatment, and Prevention. July 22-25, 2007. Sydney. Abstract WEAB305

2. Martin M, Klein T, Dong B, et al: Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing. Clin Pharmacol Ther 2012;91(4):734-738

3. Martin M, Hoffman J, Freimuth R, et al: Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther 2014;95(5):499-500

4. Faruki H, Heine U, Brown T, et al: HLA-B*5701 clinical testing: early experience in the United States. Pharmacogenet Genom 2007;17:857-860

5. Sun HY, Hung CC, Lin PH, et al: Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J. Antimicrob Chemother 2007;60:599-604

Analytic Time

1 day (Not reported Saturday or Sunday)

Method Name

Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR)


1. New York Clients-Informed consent is required. Please document on the request form or electronic order that a copy is on file. An Informed Consent for Genetic Testing (T576) is available in Special Instructions.

2. If not ordering electronically, complete, print, and send a Pharmacogenomics Test Request Form (T797) with the specimen (

Mayo Medical Laboratories | Genetics and Pharmacogenomics Catalog Additional Information: